Skull Base Chordoma: Long-Term Observation and Evaluation of Prognostic Factors after Surgical Resection

2021 ◽  
Vol 69 (6) ◽  
pp. 1608
Author(s):  
Amrit Roy ◽  
Anshu Warade ◽  
AshishK Jha ◽  
BasantK Misra
Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 339
Author(s):  
Giulia Buizza ◽  
Chiara Paganelli ◽  
Emma D’Ippolito ◽  
Giulia Fontana ◽  
Silvia Molinelli ◽  
...  

Skull-base chordoma (SBC) can be treated with carbon ion radiotherapy (CIRT) to improve local control (LC). The study aimed to explore the role of multi-parametric radiomic, dosiomic and clinical features as prognostic factors for LC in SBC patients undergoing CIRT. Before CIRT, 57 patients underwent MR and CT imaging, from which tumour contours and dose maps were obtained. MRI and CT-based radiomic, and dosiomic features were selected and fed to two survival models, singularly or by combining them with clinical factors. Adverse LC was given by in-field recurrence or tumour progression. The dataset was split in development and test sets and the models’ performance evaluated using the concordance index (C-index). Patients were then assigned a low- or high-risk score. Survival curves were estimated, and risk groups compared through log-rank tests (after Bonferroni correction α = 0.0083). The best performing models were built on features describing tumour shape and dosiomic heterogeneity (median/interquartile range validation C-index: 0.80/024 and 0.79/0.26), followed by combined (0.73/0.30 and 0.75/0.27) and CT-based models (0.77/0.24 and 0.64/0.28). Dosiomic and combined models could consistently stratify patients in two significantly different groups. Dosiomic and multi-parametric radiomic features showed to be promising prognostic factors for LC in SBC treated with CIRT.


2018 ◽  
Vol 109 ◽  
pp. 307-327 ◽  
Author(s):  
Ming-Xiang Zou ◽  
Guo-Hua Lv ◽  
Qian-Shi Zhang ◽  
Shao-Fu Wang ◽  
Jing Li ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Yutao Shen ◽  
Mingxuan Li ◽  
Yujia Xiong ◽  
Songbai Gui ◽  
Jiwei Bai ◽  
...  

BackgroundThe prognostic factors of skull base chordoma associated with outcomes of patients after surgery remain inadequately identified. This study was designed to identify a novel prognostic factor for patients with skull base chordoma.MethodUsing a proteomic technique, the tumor biomarkers that were upregulated in the rapid-recurrence group of chordoma were screened and then narrowed down by bioinformatic analysis. Finally one potential biomarker was chosen for validation by immunohistochemistry using tissue microarray (TMA). A total of 187 patients included in TMA were randomly divided into two cohorts, the training cohort included 93 patients and the validation cohort included 94 patients. Kaplan-Meier survival analysis was used to assess the patients’ survival. Univariable and multivariable Cox regression analysis were used to identify prognostic factors predicting recurrence-free survival (RFS). CCK-8 assay, clonal formation assay and transwell assay were used to test the effect of asparagine synthetase (ASNS) on the proliferation, migration and invasion in chordoma cell lines.ResultsAmong 146 upregulated proteins, ASNS was chosen as a potential prognostic biomarker after bioinformatics analysis. The H-scores of ASNS ranged from 106.27 to 239.58 in TMA. High expression of ASNS was correlated with shorter RFS in both the training cohort (p = 0.0093) and validation cohort (p < 0.001). Knockdown of ASNS by small interfering RNA (siRNA) inhibited the growth, colony formation, migration and invasion of chordoma cells in vitro.ConclusionThis study indicates that high expression of ASNS is correlated with poor prognosis of patients with skull base chordoma. ASNS may be a useful prognostic factor for patients with skull base chordoma.


2015 ◽  
Vol 76 (S 01) ◽  
Author(s):  
Naweed Chowdhury ◽  
Joshua Mark ◽  
David Beahm ◽  
Roukouz Chamoun ◽  
Terry Tsue ◽  
...  

Head & Neck ◽  
2020 ◽  
Vol 42 (9) ◽  
pp. 2607-2613 ◽  
Author(s):  
Masashi Koto ◽  
Hiroaki Ikawa ◽  
Takashi Kaneko ◽  
Yasuhito Hagiwara ◽  
Kazuhiko Hayashi ◽  
...  

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii458-iii458
Author(s):  
Pei Shuen Lim ◽  
Sébastien Tran ◽  
Stephanie G C Kroeze ◽  
Alessia Pica ◽  
Jan Hrbacek ◽  
...  

Abstract BACKGROUND The use of highly conformal proton therapy in adolescents and young adults (AYAs) for management of brain/skull-base tumours is becoming increasingly common. This study aims to assess the long-term clinical outcomes, prognostic factors and employment status of AYAs (15–39 years) treated with pencil-beam-scanning proton-therapy (PT). METHODS Between 1997–2018, 176 AYAs were treated with PT at the Paul Scherrer Institute. Median age was 30 years (range, 15–39) and the male/female ratio was 0.8. RESULTS After a median follow-up of 66 months (range, 12–236), 24 (13.6%) local failures and 1 (0.6%) distant failure were observed between 6 and 152 months after PT. The most common histologies treated were chordomas/chondrosarcomas (61.4%), followed by meningiomas (14.2%) and gliomas (15.3%). The 6-year local-control (LC), distant-progression-free survival and overall-survival (OS) rate was 83.2%, 97.4% and 90.2% respectively. On univariate analysis, age ≥24 years was a negative prognostic factor for LC. Recurrent disease, infratentorial tumours and low-grade-glioma histology were poor prognostic factors for both LC and OS. The 6-year ≥G3 PT-related late toxicity-free survival was 88.5%. The moderate-high grade late toxicity crude rates were 37.8% G2, 12.2% G3, 0.6% G4 and 0.6% G5. No secondary malignancies were observed. The unemployment rate was 7.3% at PT, rising to 25.3% at survivorship. High-grade(≥G3) toxicity rate in the unemployed vs employed group was 21% vs 8.5%. CONCLUSION PT is an effective treatment for AYAs with brain/skull-base tumours with good tumour control and acceptable long-term toxicity. Despite having satisfactory clinical outcomes, around 1 in 4 AYAs surviving brain/skull base tumours are unemployed.


2001 ◽  
Vol 10 (3) ◽  
pp. 1-5 ◽  
Author(s):  
Eugen B. Hug

Fractionated proton beam radiotherapy has been used for skull base tumors in the United States since the mid-70s, and more than 300 patients in whom diagnosis of chordoma of the skull base has been made have been treated. The ability to achieve high degrees of radiation dose conformity by using protons has resulted in higher radiation doses than can be delivered with conventional radiotherapy in the base of skull. High target volume doses have led to improved tumor control and patient survival. Side effects such as severe toxicity are acceptable considering the alternatives of uncontrolled tumor growth. The authors of various analyses have identified prognostic factors that can be used to predict a patient's chance of treatment success. On the horizon are important technical developments that will further increase dose conformity and increase target doses. In this paper the author reviews long-term outcome data and prognostic predictors for survival of patients with skull base chordomas based on the largest worldwide patient series.


Sign in / Sign up

Export Citation Format

Share Document